question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
85,2026-02-01,Structured Query,What reactions convert ATP to ADP during phosphate transfer?,True,True,True,0.6666666666666666,"Phosphate transfer reactions that convert ATP to ADP are catalyzed by enzymes called **kinases** (or phosphotransferases). Here are the main types:

## Common ATP → ADP Phosphate Transfer Reactions:

### 1. **Substrate-Level Phosphorylation**
- **Phosphoglycerate kinase**: 1,3-bisphosphoglycerate + ADP → 3-phosphoglycerate + ATP (reversible)
- **Pyruvate kinase**: Phosphoenolpyruvate + ADP → Pyruvate + ATP

### 2. **Hexokinase/Glucokinase Reactions**
- Glucose + ATP → Glucose-6-phosphate + ADP
- First step of glycolysis

### 3. **Phosphofructokinase**
- Fructose-6-phosphate + ATP → Fructose-1,6-bisphosphate + ADP
- Committed step of glycolysis

### 4. **Protein Kinases**
- Protein + ATP → Phosphoprotein + ADP
- Examples: protein kinase A, protein kinase C, tyrosine kinases
- Critical for cell signaling

### 5. **Creatine Kinase**
- Creatine + ATP → Phosphocreatine + ADP
- Energy storage in muscle

### 6. **Other Metabolic Kinases**
- **Nucleoside kinases**: deoxyribonucleoside + ATP → dNMP + ADP
- **Thymidine kinase**, **adenylate kinase**, etc.

## General Mechanism:
ATP transfers its γ-phosphate group to an acceptor molecule (substrate), releasing ADP and creating a phosphorylated product. The phosphate group transfer is typically facilitated by Mg²⁺ ions.",,7.826504945755005,49,443,True,True,0.7777777777777778,"Excellent! Now I have a comprehensive set of reactions. Let me provide the user with a detailed answer about ATP to ADP phosphate transfer reactions.

Based on my search of the Rhea biochemical reaction database, here are the major types of reactions that convert ATP to ADP during phosphate transfer:

## **1. Sugar Phosphorylation (Hexokinases)**
These enzymes transfer phosphate from ATP to hydroxyl groups on sugars:

- **Glucose phosphorylation**: `D-glucose + ATP = D-glucose 6-phosphate + ADP + H⁺` (RHEA:17825)
- **Fructose phosphorylation**: `D-fructose + ATP = D-fructose 6-phosphate + ADP + H⁺` (RHEA:16125)
- **Mannose phosphorylation**: `D-mannose + ATP = D-mannose 6-phosphate + ADP + H⁺` (RHEA:11028)
- **General hexose phosphorylation**: `a D-hexose + ATP = a D-hexose 6-phosphate + ADP + H⁺` (RHEA:22740)

## **2. Glycolysis/Gluconeogenesis Reactions**

- **Phosphofructokinase**: `β-D-fructose 6-phosphate + ATP = β-D-fructose 1,6-bisphosphate + ADP + H⁺` (RHEA:16109)
- **Pyruvate kinase (reverse)**: `pyruvate + ATP = phosphoenolpyruvate + ADP + H⁺` (RHEA:18157)

## **3. Lipid Metabolism**

- **Glycerol kinase**: `glycerol + ATP = sn-glycerol 3-phosphate + ADP + H⁺` (RHEA:21644)
- **Diacylglycerol kinase**: `a 1,2-diacyl-sn-glycerol + ATP = a 1,2-diacyl-sn-glycero-3-phosphate + ADP + H⁺` (RHEA:10272)

## **4. Sphingolipid Metabolism**

- **Sphinganine kinase**: `sphinganine + ATP = sphinganine 1-phosphate + ADP + H⁺` (RHEA:15465)

## **5. Energy Storage/Transfer**

- **Creatine kinase**: `creatine + ATP = N-phosphocreatine + ADP + H⁺` (RHEA:17157)
- **Adenylate kinase**: `AMP + ATP = 2 ADP` (RHEA:12973)
- **Nucleotide phosphorylation**: `GMP + ATP = GDP + ADP` (RHEA:20780)

## **6. Amino Sugar Phosphorylation**

- **N-acetylglucosamine kinase**: `N-acetyl-D-glucosamine + ATP = N-acetyl-D-glucosamine 6-phosphate + ADP + H⁺` (RHEA:17417)
- **Glucosamine kinase**: `D-glucosamine + ATP = D-glucosamine 6-phosphate + ADP + H⁺` (RHEA:10948)

These reactions all share the common mechanism of **transferring the terminal (γ) phosphate group from ATP to an acceptor molecule**, producing ADP and a phosphorylated product. The phosphate transfer is typically coupled with the release of a proton (H⁺), and these reactions are catalyzed by enzymes called **kinases**.",,61.77730107307434,37,1978,16121,236964,"mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_rhea_entity","[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP ADP phosphate transfer"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP = ADP + phosphate"", ""limit"": 100}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""ATP ADP phosphorylation"", ""limit"": 100}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""kinase"", ""limit"": 100}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""glucose ATP"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""hexokinase"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""phosphoryl transfer"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""fructose ATP ADP"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""protein kinase ATP"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""phosphofructokinase"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""pyruvate kinase"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""creatine phosphate"", ""limit"": 30}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""glycerol ATP"", ""limit"": 30}}]",VALUABLE,Kinase reactions that consume ATP and produce ADP during phosphoryl group transfer,"COMPLEX QUERY requiring compound-product relationship knowledge.

Databases/Resources: Rhea, ChEBI

Knowledge Required:
- Boolean bif:contains: ""('ATP' AND 'ADP')""
- Reaction-side relationship for substrate vs product
- rhea:status rhea:Approved filter
- Relevance scoring option

Without proper knowledge: Cannot properly search for compound pairs in reactions.

Verified in rhea_exploration.md Pattern 6."
86,2026-02-01,Structured Query,Find all subtypes of autophagy in Gene Ontology including their specific functions.,True,True,True,0.6428571428571429,"# Subtypes of Autophagy in Gene Ontology

Based on Gene Ontology classification, autophagy has several major subtypes defined by their mechanisms and cargo specificity:

## Major Autophagy Subtypes

### 1. **Macroautophagy** (GO:0016236)
- The major form involving double-membrane autophagosome formation
- Engulfs bulk cytoplasmic contents, organelles, and protein aggregates
- Functions: starvation response, quality control, development

### 2. **Microautophagy** (GO:0016237)
- Direct engulfment of cytoplasmic material by lysosome/vacuole membrane invagination
- Functions: membrane homeostasis, organelle turnover

### 3. **Chaperone-Mediated Autophagy (CMA)** (GO:0061684)
- HSC70-mediated selective protein degradation
- Targets proteins with KFERQ-like motifs
- Functions: protein quality control, metabolic regulation

## Selective Autophagy Subtypes (Cargo-Specific)

### 4. **Mitophagy** (GO:0000422)
- Selective degradation of mitochondria
- Functions: mitochondrial quality control, metabolic adaptation

### 5. **Pexophagy** (GO:0034727)
- Selective degradation of peroxisomes
- Functions: peroxisome turnover and homeostasis

### 6. **Reticulophagy (ER-phagy)** (GO:0061709)
- Selective degradation of endoplasmic reticulum
- Functions: ER quality control, ER remodeling

### 7. **Ribophagy** (GO:0034497)
- Selective degradation of ribosomes
- Functions: ribosome quality control, adaptation to nutrient conditions

### 8. **Nucleophagy** (GO:0044804)
- Selective degradation of nuclear components
- Functions: nuclear quality control

### 9. **Aggrephagy** (GO:0035973)
- Selective degradation of protein aggregates
- Functions: protein quality control, neurodegeneration prevention

### 10. **Xenophagy** (GO:0098792)
- Selective degradation of intracellular pathogens
- Functions: innate immunity, pathogen clearance

### 11. **Lipophagy** (GO:0044243)
- Selective degradation of lipid droplets
- Functions: lipid metabolism, energy homeostasis

### 12. **Glycophagy** (GO:0061738)
- Selective degradation of glycogen
- Functions: glycogen metabolism

### 13. **Ferritinophagy** (GO:0140357)
- Selective degradation of ferritin
- Functions: iron homeostasis

These subtypes reflect the diverse and specific roles autophagy plays in cellular homeostasis, quality control, immunity, and metabolism.",,12.23318600654602,55,716,True,True,0.6428571428571429,"Perfect! Now I have comprehensive information about all autophagy subtypes in Gene Ontology. Let me organize this information for you.

## Autophagy Subtypes in Gene Ontology

I've found all subtypes of autophagy (GO:0006914) in the Gene Ontology. Here's a comprehensive overview organized by category:

### **Main Autophagy Definition:**
**Autophagy (GO:0006914)**: The cellular catabolic process in which cells digest cellular materials, such as organelles and other macromolecular constituents, or non-self materials such as intracellular pathogens. Autophagy serves to provide essential nutrients under conditions of cellular stress; or can remodel intracellular structures during cell differentiation.

---

## **Three Major Types of Autophagy**

### 1. **Macroautophagy (GO:0016236)**
The autophagic process that proceeds via the formation of an autophagosome.

**Selective Macroautophagy Subtypes:**

- **Mitophagy (GO:0000423)** - Selective degradation of mitochondria
  - **Type 1 Mitophagy (GO:0180045)** - Degradation of functional mitochondria during nutrient deprivation or to remove excess mitochondria
  - **Type 2 Mitophagy (GO:0061734)** - Degradation initiated by mitochondrial depolarization and Parkin binding to remove dysfunctional/damaged mitochondria

- **Pexophagy (GO:0000425)** - Selective degradation of peroxisomes

- **Xenophagy (GO:0098792)** - Selective degradation of intracellular pathogens or pathogen components (e.g., viral capsids)

- **Aggrephagy (GO:0035973)** - Selective degradation of protein aggregates

- **Ribophagy (GO:0034517)** - Selective degradation of mature ribosomes

- **Reticulophagy (GO:0061709)** - Selective degradation of parts of the endoplasmic reticulum

- **Nucleophagy (GO:0044804)** - Degradation of damaged or non-essential parts of the nucleus, or an entire nucleus

- **Lipophagy (GO:0061724)** - Selective degradation of lipid droplets

- **Glycophagy (GO:0061723)** - Selective degradation of glycogen

- **Lysophagy (GO:0062093)** - Selective degradation of damaged lysosomes

- **Proteaphagy (GO:0061816)** - Selective degradation of proteasomes

### 2. **Microautophagy (GO:0016237)**
Autophagy where cytosolic components are ingested by late endosomes, lysosomes or vacuoles through direct invagination of the compartment membrane without prior sequestration into an autophagosome.

**Microautophagy Subtypes:**

- **Micromitophagy (GO:0000424)** - Degradation of mitochondria by microautophagy

- **Micropexophagy (GO:0000426)** - Degradation of peroxisomes by microautophagy

- **Microlipophagy (GO:0140504)** - Degradation of lipid droplets by microautophagy

- **Late Endosomal Microautophagy (GO:0061738)** - Chaperone-tagged cytosolic proteins are directly transferred into and degraded in late endosomes

- **Piecemeal Microautophagy of the Nucleus (GO:0034727)** - Degradation of the cell nucleus by microautophagy

### 3. **Chaperone-Mediated Autophagy (GO:0061684)**
Autophagy that begins when chaperones and co-chaperones recognize a target motif and unfold the substrate protein. The proteins are then transported to the lysosome where they are degraded.

---

## **Other Autophagy-Related Processes**

### **Organelle-Specific Autophagy:**

- **Autophagy of Mitochondrion (GO:0000422)** - General term for autophagic degradation of mitochondria
  - Includes: mitophagy, micromitophagy, and mitophagy by internal vacuole formation

- **Autophagy of Peroxisome (GO:0030242)** - General term for peroxisome degradation
  - Includes: pexophagy and micropexophagy

- **Mitophagy by Internal Vacuole Formation (GO:0035695)** - Mitochondria are directly engulfed by a lysosome-like vacuole

### **Secretory Granule Autophagy:**

- **Crinophagy (GO:0160155)** - Direct fusion of abnormal, excess or obsolete secretory granules with lysosomes, maintaining homeostasis in endocrine and exocrine cells

---

## **Key Functional Categories:**

1. **Quality Control**: Type 2 mitophagy, lysophagy, aggrephagy, xenophagy
2. **Metabolic Regulation**: Type 1 mitophagy, lipophagy, glycophagy
3. **Organelle Turnover**: Pexophagy, reticulophagy, nucleophagy
4. **Cellular Remodeling**: Ribophagy, proteaphagy, crinophagy
5. **Protein Degradation**: Chaperone-mediated autophagy

This classification shows the remarkable specificity of autophagy processes, with distinct pathways for virtually every major cellular component and varying mechanisms (macro-, micro-, and chaperone-mediated) depending on the substrate and cellular context.",,39.80658984184265,12,1694,31558,93066,"mcp__ols__searchClasses, mcp__ols__getDescendants","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""autophagy"", ""ontologyId"": ""go""}}, {""name"": ""mcp__ols__getDescendants"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0006914"", ""pageSize"": 100}}]",VALUABLE,"25 descendant terms including macroautophagy, microautophagy, mitophagy, chaperone-mediated autophagy, and other autophagy subtypes with their definitions","COMPLEX QUERY requiring hierarchical ontology navigation and property retrieval.

Databases/Resources: GO

Knowledge Required:
- rdfs:subClassOf traversal for hierarchy
- FROM clause for consistent results
- Property retrieval for definitions and labels
- STRSTARTS filter for GO URI identification

Without proper knowledge: Missing FROM clause causes duplicated/inconsistent results.

Verified in go_exploration.md Pattern 2 and Pattern 6."
87,2026-02-01,Integration,What proteins have both PDB structures and involvement in autophagy pathways?,True,True,True,0.5,"I can provide information about several well-characterized proteins that have both PDB structures and established roles in autophagy pathways:

## Core Autophagy Proteins (ATG proteins):

1. **LC3/ATG8 family proteins** - Essential for autophagosome formation
   - LC3B (MAP1LC3B) - Multiple PDB structures available
   - GABARAP family members
   - These are ubiquitin-like proteins crucial for autophagosome membrane expansion

2. **ATG4** - Cysteine protease that processes LC3
   - ATG4B has several PDB structures
   - Cleaves LC3 for lipidation

3. **ATG7** - E1-like enzyme
   - Crystal structures available
   - Activates ATG8/LC3 and ATG12

4. **ATG3** - E2-like enzyme
   - Multiple structures in PDB
   - Conjugates LC3 to phosphatidylethanolamine

5. **ATG5-ATG12-ATG16L1 complex**
   - Structures of components available
   - E3-like activity for LC3 lipidation

## Regulatory Proteins:

6. **mTOR (mechanistic Target of Rapamycin)**
   - Master regulator of autophagy
   - Several structures available

7. **ULK1/ATG1** - Serine/threonine kinase
   - Initiates autophagy
   - Crystal structures of kinase domain available

8. **Beclin 1** - Part of VPS34 complex
   - Multiple structures in complexes

9. **VPS34 (PIK3C3)** - Class III PI3-kinase
   - Generates PI3P for autophagosome formation

These proteins are among the most structurally characterized components of the autophagy machinery.",,10.367601871490479,53,443,True,True,0.7,"Perfect! Now let me create a comprehensive summary of all the autophagy proteins with PDB structures that I've found:

## Proteins with Both PDB Structures and Involvement in Autophagy Pathways

I've identified numerous human proteins that have both PDB structures and direct involvement in autophagy pathways. Here are the key proteins organized by their functional roles:

### **Core ATG Proteins (Autophagy-Related Proteins)**

1. **ATG3** (Q9NT62) - Ubiquitin-like-conjugating enzyme
   - PDB IDs: 8AFI, 8FKM, 4NAW

2. **ATG5** (Q9H1Y0) - Autophagy protein 5
   - PDB IDs: 5NPV, 5NPW, 7W36, 4TQ1, 4GDK, 4GDL, 4NAW, 4TQ0, 5D7G

3. **ATG12** (O94817) - Ubiquitin-like protein
   - PDB IDs: 4GDK, 4GDL, 4NAW

4. **ATG13** (O75143) - Autophagy-related protein 13
   - PDB IDs: 5XUY, 5XV3, 8SRQ, 5XV6, 8SQZ, 5XV4, 8SRM, 3WAO, 3WAP, 3WAN, 5C50, 5XV1, 8DO8, 8SOI, 6HYN

5. **ATG16L1** (Q676U5) - Autophagy-related protein 16-1
   - PDB IDs: 5NPV, 5NPW, 5NUV, 5ZYX, 7F69, 7W36, 7XFR, 4GDK, 4GDL, 4NAW, 4TQ0, 5D7G

6. **ATG4A** (Q8WYN0) - Cysteine protease ATG4A
   - PDB IDs: 2P82

7. **ATG4B** (Q9Y4P1) - Cysteine protease ATG4B
   - PDB IDs: 2CY7, 2D1I, 2Z0D, 2Z0E, 2ZZP, 5LXH, 5LXI

8. **ATG14** (Q6ZNE5) - Autophagy-related protein 14-like protein (Barkor)
   - PDB IDs: 6HOL, 8SRQ, 8SOR

9. **ATG101** (Q9BSB4) - Autophagy-related protein 101
   - PDB IDs: 5XUY, 5XV3, 5XV4, 5XV6, 8DO8, 5C50, 5XV1, 4WZG

10. **ATG2A** (Q2TAZ0) - Autophagy-related protein 2A
    - PDB IDs: 8SBK, 8SBL, 6KLR

### **ULK1 Complex**

11. **ULK1** (O75385) - Unc-51-like autophagy activating kinase 1
    - PDB IDs: 4WNO, 4WNP, 5CI7, 6HYO, 6MNH, 6QAS, 8SV9, 8SOI, 8SQZ, 8SRM, 8SRQ

### **Beclin 1 Complex**

12. **BECN1** (Q14457) - Beclin-1
    - PDB IDs: 6HOJ, 6HOK, 7BL1, 2PON, 6DCN, 6DCO, 4DDP, 5EFM, 5HHE, 6HOI, 8SRQ, 3DVU, 4MI8, 2P1L, 5VAY, 8SOR, 5VAU, 5VAX

13. **AMBRA1** (Q9C0C7) - Activating molecule in BECN1-regulated autophagy protein 1
    - PDB IDs: 8WQR

### **LC3/GABARAP Family (Ubiquitin-like Modifiers)**

14. **MAP1LC3A** (Q9H492) - Microtubule-associated protein 1 light chain 3 alpha
    - PDB IDs: 5CX3, 3WAN, 5DPR

15. **MAP1LC3B** (Q9GZQ8) - Microtubule-associated protein 1 light chain 3 beta
    - PDB IDs: 5W9A, 6LAN, 5MS2, 5MS5, 5XAD, 5D94, 3WAO, 2LUE, 2N9X, 3VTU, 3VTV, 3VTW, 3X0W, 4WAA, 5DCN, 5GMV, 5V4K, 6J04, 7ELG, 1V49, 2ZJD, 5MS6, 5XAC, 5XAE

16. **GABARAP** (O95166) - Gamma-aminobutyric acid receptor-associated protein
    - PDB IDs: 6HYM, 6HOG, 7ZL7, 7BRQ, 6YOP, 7ZKR, 7BRU, 6HOH, 3D32, 1KOT, 1GNU, 6HYL, 6HYO, 3WIM, 7YO9, 7LSW, 6HOJ, 6HOK, 5DPS, 7BV4, 7VED, 8T2N, 8T2M, 4XC2, 7BRT, 7LT6, 7EA7, 8AFI, 1KLV, 6HB9, 7AA8, 7VEC, 6HYN, 3DOW, 1KM7

17. **GABARAPL2** (P60520) - GABA(A) receptor-associated protein-like 2
    - PDB IDs: 6H8C, 7LK3, 7YO8, 4CO7

### **Cargo Receptors/Adaptors**

18. **SQSTM1/p62** (Q13501) - Sequestosome-1
    - PDB IDs: 6KHZ, 6TH3, 2K0B, 2JY8, 7R1O, 6JM4, 2JY7, 5YPG, 6TGY, 1Q02, 6MJ7, 5YP7, 4UF9, 5YPF, 5YPE, 5YPC, 4MJS, 5YP8, 4UF8, 5YPB, 5YPH, 2KNV, 5YPA

19. **NBR1** (Q14596) - Next to BRCA1 gene 1 protein
    - PDB IDs: 2MJ5, 2G4S, 2L8J, 1WJ6, 2BKF, 2CP8, 2MGW, 4OLE

20. **OPTN** (Q96CV9) - Optineurin
    - PDB IDs: 5B83, 7CZM, 5AAZ, 5EOA, 5EOF, 2LUE, 3VTV, 3VTW, 2LO4

### **Regulatory Kinases**

21. **TBK1** (Q9UHD2) - TANK-binding kinase 1
    - PDB IDs: 6O8B, 5EOA, 5EOF, 5EP6, 4EFO, 4EUT, 4EUU, 5W5V, 6BNY, 6BOD, 6BOE, 6CQ0, 6CQ4, 6CQ5, 6RSR, 6RST, 6RSU, 6NT9, 4IM0, 4IM2, 4IM3, 4IW0, 4IWO, 4IWP, 4IWQ

### **Key Insights:**

- **Most structures available**: MAP1LC3B (26+ structures), GABARAP (35+ structures), SQSTM1/p62 (19+ structures), BECN1 (18+ structures), and TBK1 (22+ structures)
- **Core autophagy machinery**: Nearly all components of the core ATG conjugation systems (ATG5, ATG12, ATG16L1, ATG3) have structures
- **Initiation complex**: Both ULK1 and its binding partners (ATG13, ATG101) have multiple structures
- **LC3 family**: Extensive structural coverage of LC3 and GABARAP family members, which are essential for autophagosome formation
- **Selective autophagy**: Multiple cargo receptor proteins (SQSTM1/p62, NBR1, OPTN) have PDB structures, showing how specific cargos are recognized

These proteins represent the major molecular machinery of autophagy, from initiation (ULK1 complex), through nucleation (Beclin 1 complex), to autophagosome formation (ATG conjugation systems) and cargo recognition (receptor proteins).",,182.1746802330017,48,7834,35702,857252,"mcp__ols__searchClasses, mcp__togomcp__search_reactome_entity, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""autophagy"", ""pageSize"": 20}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""autophagy"", ""rows"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?protein ?proteinLabel ?gene ?pdbID\nWHERE {\n  ?protein a up:Protein ;\n           rdfs:label ?proteinLabel ;\n           up:organism <http://purl.uniprot.org/taxonomy/9606> ;\n           up:annotation ?annotation .\n  \n  ?annotation a up:Function_Annotation ;\n              rdfs:comment ?comment .\n  \n  FILTER(CONTAINS(LCASE(?comment), \""autophagy\""))\n  \n  ?protein up:encodedBy ?geneNode .\n  ?geneNode skos:prefLabel ?gene .\n  \n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n  BIND(SUBSTR(STR(?pdb), 33) AS ?pdbID)\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""autophagy human"", ""limit"": 20}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene ?pdbID\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/O75143>\n    <http://purl.uniprot.org/uniprot/Q9BSB4>\n    <http://purl.uniprot.org/uniprot/Q676U5>\n    <http://purl.uniprot.org/uniprot/Q6ZNE5>\n    <http://purl.uniprot.org/uniprot/Q9H492>\n    <http://purl.uniprot.org/uniprot/O94817>\n    <http://purl.uniprot.org/uniprot/Q9H1Y0>\n    <http://purl.uniprot.org/uniprot/Q9H0Y0>\n    <http://purl.uniprot.org/uniprot/Q7Z3C6>\n    <http://purl.uniprot.org/uniprot/Q8WYN0>\n  }\n  \n  ?protein up:encodedBy ?geneNode .\n  ?geneNode <http://www.w3.org/2004/02/skos/core#prefLabel> ?gene .\n  \n  OPTIONAL {\n    ?protein rdfs:seeAlso ?pdb .\n    ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n    BIND(SUBSTR(STR(?pdb), 33) AS ?pdbID)\n  }\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?uniprotID ?gene ?pdbID\nWHERE {\n  ?protein a up:Protein ;\n           up:organism <http://purl.uniprot.org/taxonomy/9606> ;\n           up:mnemonic ?uniprotID ;\n           up:encodedBy ?geneNode .\n  \n  ?geneNode skos:prefLabel ?gene .\n  FILTER(CONTAINS(?gene, \""ATG\"") || CONTAINS(?gene, \""LC3\"") || CONTAINS(?gene, \""BECN\""))\n  \n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n  BIND(SUBSTR(STR(?pdb), 33) AS ?pdbID)\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/Q9H1Y0>\n    <http://purl.uniprot.org/uniprot/O94817>\n    <http://purl.uniprot.org/uniprot/Q9H492>\n    <http://purl.uniprot.org/uniprot/Q9GZQ8>\n    <http://purl.uniprot.org/uniprot/Q8WYN0>\n    <http://purl.uniprot.org/uniprot/Q9Y4P1>\n    <http://purl.uniprot.org/uniprot/O95352>\n    <http://purl.uniprot.org/uniprot/Q9NT62>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/Q60930>\n    <http://purl.uniprot.org/uniprot/O95352>\n    <http://purl.uniprot.org/uniprot/Q13501>\n    <http://purl.uniprot.org/uniprot/Q9H0Y0>\n    <http://purl.uniprot.org/uniprot/O75143>\n    <http://purl.uniprot.org/uniprot/Q96AG3>\n    <http://purl.uniprot.org/uniprot/P49756>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/Q14457>\n    <http://purl.uniprot.org/uniprot/O60238>\n    <http://purl.uniprot.org/uniprot/O00141>\n    <http://purl.uniprot.org/uniprot/Q8TEY7>\n    <http://purl.uniprot.org/uniprot/Q96BY7>\n    <http://purl.uniprot.org/uniprot/Q9BSB4>\n    <http://purl.uniprot.org/uniprot/Q676U5>\n    <http://purl.uniprot.org/uniprot/Q9Y4P1>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/O75385>\n    <http://purl.uniprot.org/uniprot/O95989>\n    <http://purl.uniprot.org/uniprot/Q8IYU8>\n    <http://purl.uniprot.org/uniprot/Q9H4M9>\n    <http://purl.uniprot.org/uniprot/O94759>\n    <http://purl.uniprot.org/uniprot/Q2TAZ0>\n    <http://purl.uniprot.org/uniprot/Q86Y32>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/O95352>\n    <http://purl.uniprot.org/uniprot/Q9BXW9>\n    <http://purl.uniprot.org/uniprot/Q9Y4P3>\n    <http://purl.uniprot.org/uniprot/Q6ZNE5>\n    <http://purl.uniprot.org/uniprot/Q9C0C7>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""ATG7 human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/O95352>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/Q14980>\n    <http://purl.uniprot.org/uniprot/Q9BZZ5>\n    <http://purl.uniprot.org/uniprot/Q86V97>\n    <http://purl.uniprot.org/uniprot/Q86TB9>\n    <http://purl.uniprot.org/uniprot/Q96IX5>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""NBR1 OPTN autophagy human"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""NBR1 human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""OPTN human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/Q14596>\n    <http://purl.uniprot.org/uniprot/Q96CV9>\n    <http://purl.uniprot.org/uniprot/Q9UHD2>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?gene (STRAFTER(STR(?pdb), \""pdb/\"") AS ?pdbID)\nWHERE {\n  VALUES ?protein {\n    <http://purl.uniprot.org/uniprot/O95166>\n    <http://purl.uniprot.org/uniprot/P60520>\n    <http://purl.uniprot.org/uniprot/Q9H2M9>\n  }\n  \n  ?protein up:encodedBy/skos:prefLabel ?gene .\n  ?protein rdfs:seeAlso ?pdb .\n  ?pdb up:database <http://purl.uniprot.org/database/PDB> .\n}\nLIMIT 100""}}]",VALUABLE,Human proteins with autophagy GO annotations that also have PDB structural data,"COMPLEX QUERY requiring multi-database integration.

Databases/Resources: UniProt, GO, PDB

Knowledge Required:
- GO annotation via up:classifiedWith
- PDB cross-references via rdfs:seeAlso with URI filtering
- up:reviewed 1 filter essential
- Multiple criteria combination

Without proper knowledge: Cannot combine GO and PDB cross-references correctly.

Verified in uniprot_exploration.md (complex filtering patterns)."
88,2026-02-01,Integration,What external database links are available for ChEMBL compound CHEMBL1380?,True,False,True,0.6666666666666666,"I don't have specific information about the external database links for ChEMBL compound CHEMBL1380 in my training data. 

However, I can tell you that ChEMBL compounds typically have cross-references to various external databases such as:

- PubChem
- DrugBank
- UniProt (for protein targets)
- PDB (Protein Data Bank)
- Wikipedia
- KEGG
- MetaboLights
- And others

To find the specific external database links for CHEMBL1380, you would need to:
1. Visit the ChEMBL website (www.ebi.ac.uk/chembl)
2. Search for CHEMBL1380
3. Look at the compound report page which lists all available cross-references

I cannot provide the exact external links for this specific compound without accessing the ChEMBL database directly.",,4.810497999191284,56,202,True,True,0.6666666666666666,"Based on my query of the ChEMBL RDF database, here are the **external database links available for ChEMBL compound CHEMBL1380 (Abacavir)**:

## External Database Cross-References:

1. **ChEBI (Chemical Entities of Biological Interest)**
   - ChEBI ID: CHEBI:421707
   - URI: http://purl.obolibrary.org/obo/CHEBI_421707
   - Direct link: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A421707

2. **DrugBank**
   - DrugBank ID: DB01048
   - URI: http://www.drugbank.ca/drugs/DB01048

3. **PubChem Compound**
   - CID: 441300
   - URI: http://pubchem.ncbi.nlm.nih.gov/compound/441300

4. **PubChem Substance**
   - SID: 14775540
   - URI: http://pubchem.ncbi.nlm.nih.gov/substance/14775540
   - SID: 14799909
   - URI: http://pubchem.ncbi.nlm.nih.gov/substance/14799909

5. **LINCS (Library of Integrated Network-Based Cellular Signatures)**
   - LINCS ID: LSM-43340
   - URI: http://identifiers.org/lincs.smallmolecule/LSM-43340

## Additional Information:
- **Compound Name**: ABACAVIR
- **ATC Classification**: J05AF06 (Antivirals for systemic use - Nucleoside and nucleotide reverse transcriptase inhibitors)

These cross-references allow you to access additional information about Abacavir across different specialized databases, including chemical properties, drug information, biological activities, and cellular signatures.",,41.26517915725708,31,1849,7780,176943,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?database ?identifier ?url\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> cco:moleculeXref ?xref .\n  ?xref cco:xrefSrc ?database .\n  ?xref cco:xrefId ?identifier .\n  OPTIONAL { ?xref cco:xrefUrl ?url }\n}\nORDER BY ?database\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?property ?value\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> ?property ?value .\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?property ?value\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> ?property ?value .\n  FILTER(CONTAINS(STR(?property), \""xref\"") || CONTAINS(STR(?property), \""sameAs\"") || CONTAINS(STR(?property), \""exactMatch\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?property ?object\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> ?property ?object .\n  FILTER(isURI(?object) && \n         (CONTAINS(STR(?object), \""purl.\"") || \n          CONTAINS(STR(?object), \""identifiers.org\"") ||\n          CONTAINS(STR(?object), \""drugbank\"") ||\n          CONTAINS(STR(?object), \""pubchem\"") ||\n          CONTAINS(STR(?object), \""chebi\"") ||\n          ?property = skos:exactMatch ||\n          ?property = skos:closeMatch))\n}\nORDER BY ?property ?object\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT ?label ?smiles ?inchi ?inchiKey\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> skos:prefLabel ?label .\n  OPTIONAL { <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> chembl:smiles ?smiles . }\n  OPTIONAL { <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> chembl:inchi ?inchi . }\n  OPTIONAL { <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1380> chembl:inchiKey ?inchiKey . }\n}\n""}}]",CRITICAL,"DrugBank (DB01048), PubChem, and other cross-references for Abacavir","COMPLEX QUERY requiring cross-reference navigation.

Databases/Resources: ChEMBL

Knowledge Required:
- cco:moleculeXref property for cross-references
- Multiple database filters (DrugBank, PubChem, etc.)
- URI pattern recognition for different databases
- Pre-filtering for performance

Without proper knowledge: Cannot navigate cross-reference structure efficiently.

Verified in chembl_exploration.md Pattern 3 and simple queries section."
89,2026-02-01,Completeness,How many human kinases have expert curation in UniProt?,True,False,True,0.5714285714285714,"I don't have access to real-time UniProt database statistics in my training data, so I cannot provide you with the exact current number of human kinases with expert curation.

However, I can tell you that:

1. **Human kinome size**: The human kinome consists of approximately 518-538 protein kinases (the exact number varies slightly depending on classification criteria).

2. **UniProt curation levels**: UniProt entries are categorized as either:
   - **Swiss-Prot**: Expert-curated, manually annotated entries with high-quality annotation
   - **TrEMBL**: Automatically annotated entries awaiting full manual curation

3. **General trends**: Most well-studied human kinases, particularly those that are therapeutic targets or have important biological functions, typically have Swiss-Prot (expert-curated) entries. This would include most of the major kinase families like tyrosine kinases, serine/threonine kinases, etc.

To get the exact current number, you would need to:
- Query the UniProt database directly
- Use the UniProt API or search interface
- Filter for human proteins (taxonomy ID: 9606), kinase activity, and Swiss-Prot reviewed status

The number would likely be in the range of several hundred expert-curated human kinase entries, but I cannot give you a precise figure without accessing the current database.",,8.16024136543274,51,316,True,True,0.7142857142857143,"Perfect! Based on my query of the UniProt database, there are **2,006 human kinases with expert curation** in UniProt (SwissProt).

These are proteins that:
- Are from human (organism taxon 9606)
- Have been manually reviewed and expertly curated (up:reviewed true)
- Are classified with keyword annotations containing ""kinase""

Expert curation in UniProt (also known as Swiss-Prot) means these entries have been manually annotated by expert curators, ensuring high-quality, comprehensive information about the protein's function, structure, and other biological properties.",,46.27159786224365,32,1348,1779,160280,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?count)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:reviewed true ;\n           up:classifiedWith ?keyword .\n  ?keyword rdfs:label ?label .\n  FILTER(CONTAINS(LCASE(?label), \""kinase\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?kinaseCount)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:reviewed true ;\n           up:annotation ?annotation .\n  ?annotation a up:Function_Annotation .\n  ?annotation rdfs:comment ?comment .\n  FILTER(CONTAINS(LCASE(STR(?comment)), \""kinase\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX keywords: <http://purl.uniprot.org/keywords/>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?kinaseCount)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:reviewed true ;\n           up:classifiedWith keywords:Kinase .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?kinaseCount)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:reviewed true ;\n           up:classifiedWith ?keyword .\n  ?keyword a up:Keyword .\n  ?keyword up:prefLabel ?label .\n  FILTER(CONTAINS(LCASE(?label), \""kinase\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?kinaseCount)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:reviewed true ;\n           up:classifiedWith ?keyword .\n  ?keyword rdfs:label ?label .\n  FILTER(REGEX(?label, \""kinase\"", \""i\""))\n}\n""}}]",CRITICAL,Count of reviewed human proteins with kinase-related annotations,"COMPLEX QUERY requiring text search and counting.

Databases/Resources: UniProt

Knowledge Required:
- bif:contains for 'kinase' in protein names
- Property path splitting for name search
- up:reviewed 1 filter CRITICAL
- Human organism filter
- COUNT aggregation

Without proper knowledge: Property path error with bif:contains or timeout without reviewed filter.

Verified in uniprot_exploration.md Pattern 2."
90,2026-02-01,Completeness,What is the distribution of clinical significance classifications across all ClinVar variants?,True,True,False,0.125,"Based on my training knowledge of ClinVar data, the distribution of clinical significance classifications typically follows this general pattern:

## Major Categories:

1. **Benign/Likely Benign**: ~45-50% of classified variants
   - These represent the largest category
   - Includes both ""Benign"" and ""Likely benign"" classifications

2. **Uncertain Significance (VUS)**: ~30-35%
   - Variants where evidence is insufficient for definitive classification
   - This is a substantial portion reflecting diagnostic challenges

3. **Pathogenic/Likely Pathogenic**: ~15-20%
   - Disease-causing or probably disease-causing variants
   - Includes both ""Pathogenic"" and ""Likely pathogenic"" classifications

4. **Conflicting Interpretations**: ~5-10%
   - Variants with disagreement among submitters
   - Can involve any combination of the above classifications

5. **Other categories**: ~1-5%
   - Includes: drug response, risk factor, protective, affects, association, etc.
   - Relatively uncommon compared to main categories

## Important Notes:

- The exact percentages vary over time as ClinVar continuously grows and variants are reclassified
- Many variants lack clinical significance assertions entirely
- The distribution can vary significantly by gene, condition, or variant type
- There's an ongoing effort to reduce VUS classifications through improved evidence gathering

The trend over time shows increasing reclassifications from VUS to definitive categories as more evidence becomes available.",,9.466315031051636,52,344,True,False,0.1875,"Great! I was able to retrieve the distribution of clinical significance classifications across ClinVar variants. Here are the results:

## Distribution of Clinical Significance Classifications in ClinVar

Based on the query of the ClinVar database, here's the breakdown of variants by clinical significance:

| Clinical Significance | Number of Variants | Percentage |
|----------------------|-------------------|------------|
| **Uncertain significance** | 3,361,619 | 32.4% |
| **Benign** | 3,178,975 | 30.6% |
| **Likely benign** | 3,059,948 | 29.5% |
| **Pathogenic** | 714,719 | 6.9% |
| **Likely pathogenic** | 190,755 | 1.8% |
| **Conflicting interpretations** | 435 | <0.1% |

**Total variants searched:** ~4.4 million (based on initial query)

### Key Observations:

1. **Benign variants dominate** (~60%): Combined ""Benign"" and ""Likely benign"" classifications account for approximately 60% of all ClinVar variants.

2. **Large uncertainty**: About one-third (32.4%) of variants have ""Uncertain significance"" (VUS), indicating that clinical interpretation is not yet clear for these variants.

3. **Pathogenic variants** (~9%): ""Pathogenic"" and ""Likely pathogenic"" variants together represent only about 8.7% of the database.

4. **Conflicting interpretations are rare**: Only 435 variants have conflicting interpretations, suggesting relatively good concordance among submitters for most variants.

This distribution reflects the current state of variant interpretation in clinical genomics, where a significant portion of variants still require further evidence to determine their clinical impact.",,58.13995909690857,28,2186,4078,161336,"mcp__togomcp__ncbi_esearch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""1:9999999999[CHRPOS37]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""\nPREFIX clinvar: <http://purl.jp/bio/10/clinvar/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?significance (COUNT(DISTINCT ?variant) AS ?count)\nWHERE {\n  ?variant a clinvar:VariationArchiveType ;\n           clinvar:interpreted_record ?record .\n  ?record clinvar:rcv_list ?rcv_list .\n  ?rcv_list clinvar:rcv_accession ?rcv .\n  ?rcv clinvar:classifications ?class .\n  ?class clinvar:germline_classification ?germline .\n  ?germline clinvar:description ?significance .\n}\nGROUP BY ?significance\nORDER BY DESC(?count)\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?property\nWHERE {\n  ?s ?property ?o .\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""Pathogenic[CLINSIG]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""Likely pathogenic[CLINSIG]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""Benign[CLINSIG]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""Likely benign[CLINSIG]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""Uncertain significance[CLINSIG]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""Conflicting interpretations of pathogenicity[CLINSIG]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""\""Pathogenic\""[Clinical significance]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""\""Likely pathogenic\""[Clinical significance]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""\""Benign\""[Clinical significance]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""\""Likely benign\""[Clinical significance]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""\""Uncertain significance\""[Clinical significance]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""\""Conflicting interpretations of pathogenicity\""[Clinical significance]"", ""max_results"": 1}}]",VALUABLE,"Uncertain significance: 51% (1,821,577), Likely benign: 28% (993,150), Benign: 6% (213,802), Pathogenic: 6% (200,004), Conflicting: 4% (145,497)","COMPLEX QUERY requiring classification aggregation.

Databases/Resources: ClinVar

Knowledge Required:
- Property path for significance classification
- GROUP BY for aggregation
- record_status 'current' filter
- COUNT for distribution

Without proper knowledge: Cannot navigate nested classification structure.

Verified in clinvar_exploration.md Pattern 5."
91,2026-02-01,Specificity,Which GO biological processes have Reactome pathway cross-references?,True,False,False,0.42857142857142855,"I don't have access to a comprehensive, up-to-date list of which specific GO biological processes have Reactome pathway cross-references in my training data.

However, I can tell you that:

1. **General relationship**: GO (Gene Ontology) biological process terms and Reactome pathways are cross-referenced when they describe similar or overlapping biological phenomena. Reactome provides detailed pathway diagrams while GO provides hierarchical ontology terms.

2. **Common areas with cross-references** typically include:
   - Signal transduction pathways
   - Metabolic processes
   - Cell cycle processes
   - Immune system processes
   - DNA repair and replication
   - Apoptosis and cell death
   - Developmental processes

3. **How to find this information**: The most reliable way to get current cross-references would be to:
   - Query the GO database directly (using AmiGO or QuickGO browsers)
   - Check the Reactome database for their GO mappings
   - Use the GO annotation files which include database cross-references

The cross-references are maintained by both databases and updated regularly, so querying the actual databases would give you the most accurate and complete current list.",,7.1160728931427,50,270,True,False,0.42857142857142855,"Based on my investigation using the TogoID database conversion system and biological database cross-references, I can confirm that **many GO biological processes have Reactome pathway cross-references**. The relationship between GO and Reactome is bidirectional, where Reactome pathways are annotated with corresponding GO biological process terms.

Here are some examples of GO biological processes that have Reactome pathway cross-references:

## Major GO Biological Processes with Reactome Links:

### Cell Death & Cell Cycle
- **GO:0006915** - apoptotic process
- **GO:0007049** - cell cycle  
- **GO:0000075** - cell cycle checkpoint signaling

### Metabolism
- **GO:0008152** - metabolic process (broad category)
- **GO:0055086** - nucleobase-containing small molecule metabolic process
- **GO:0006687** - glycosphingolipid metabolic process
- **GO:0006778** - porphyrin-containing compound metabolic process
- **GO:0006595** - polyamine metabolic process
- **GO:0005977** - glycogen metabolic process

### Gene Expression & RNA Processing
- **GO:0006351** - DNA-templated transcription
- **GO:0006366** - transcription by RNA polymerase II
- **GO:0006412** - translation
- **GO:0016070** - RNA metabolic process
- **GO:0019538** - protein metabolic process

### DNA Processes
- **GO:0006281** - DNA repair

### Signal Transduction
- Multiple signaling-related GO terms cross-reference to Reactome signal transduction pathways

## Key Findings:

1. **Systematic cross-referencing**: The relationship is encoded in the TogoID database with the semantic relationship ""has GO biological process"" (forward from Reactome to GO) and ""is GO biological process of"" (reverse from GO to Reactome).

2. **Comprehensive coverage**: Reactome pathways cover major biological processes including metabolism, cell cycle, signal transduction, gene expression, DNA repair, immune responses, and programmed cell death.

3. **Multiple pathway mappings**: Single GO terms can map to multiple Reactome pathways (across different species and pathway variants), and conversely, related Reactome pathways may share GO term annotations.

This cross-referencing is valuable for integrating pathway-level information (Reactome) with functional annotations (GO) in biological data analysis.",,140.76214694976807,68,4488,64124,1269790,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__ols__searchClasses, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, WebSearch, mcp__togomcp__togoid_getAllRelation, mcp__togomcp__togoid_getRelation, mcp__togomcp__togoid_convertId, mcp__togomcp__search_reactome_entity, mcp__togomcp__togoid_convertId, mcp__togomcp__togoid_convertId, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__togomcp__search_reactome_entity, mcp__togomcp__togoid_convertId, mcp__togomcp__search_reactome_entity, mcp__togomcp__togoid_convertId, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?go_id ?go_label ?reactome_id\nWHERE {\n  ?go_uri a <http://www.w3.org/2002/07/owl#Class> ;\n          rdfs:label ?go_label ;\n          oboInOwl:hasDbXref ?reactome_id .\n  \n  FILTER(STRSTARTS(STR(?go_uri), \""http://purl.obolibrary.org/obo/GO_\""))\n  FILTER(CONTAINS(?go_label, \""process\"") || REGEX(STR(?go_uri), \""GO_0008150|GO_000[0-9]\""))\n  FILTER(STRSTARTS(?reactome_id, \""Reactome:\""))\n  \n  BIND(REPLACE(STR(?go_uri), \""http://purl.obolibrary.org/obo/GO_\"", \""GO:\"") AS ?go_id)\n}\nORDER BY ?go_id\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?go_term ?label ?xref\nWHERE {\n  ?go_term oboInOwl:hasDbXref ?xref ;\n           rdfs:label ?label .\n  FILTER(REGEX(?xref, \""^Reactome:\"", \""i\""))\n  FILTER(REGEX(STR(?go_term), \""GO_\""))\n}\nLIMIT 100\n""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""biological_process Reactome"", ""ontologyId"": ""go"", ""pageSize"": 50}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006915""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0007165""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006096""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT DISTINCT ?go_id ?label ?reactome_xref\nWHERE {\n  ?term rdfs:label ?label ;\n        oboInOwl:hasDbXref ?reactome_xref .\n  \n  FILTER(CONTAINS(STR(?term), \""GO_\""))\n  FILTER(REGEX(?reactome_xref, \""Reactome\"", \""i\""))\n  \n  BIND(REPLACE(STR(?term), \"".*GO_\"", \""GO:\"") AS ?go_id)\n}\nORDER BY ?go_id\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX biopax: <http://www.biopax.org/release/biopax-level3.owl#>\n\nSELECT DISTINCT ?pathway ?pathway_name ?go_term\nWHERE {\n  ?pathway a biopax:Pathway ;\n           rdfs:label ?pathway_name ;\n           biopax:xref ?xref .\n  ?xref biopax:db \""go\"" ;\n        biopax:id ?go_term .\n  \n  FILTER(CONTAINS(?go_term, \""GO:\""))\n}\nORDER BY ?go_term\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX biopax: <http://www.biopax.org/release/biopax-level3.owl#>\n\nSELECT DISTINCT ?p ?o\nWHERE {\n  ?s ?p ?o .\n  FILTER(CONTAINS(STR(?o), \""GO:\"") || CONTAINS(STR(?o), \""go\""))\n}\nLIMIT 20\n""}}, {""name"": ""WebSearch"", ""input"": {""query"": ""GO Gene Ontology biological process Reactome pathway cross-references database mapping""}}, {""name"": ""mcp__togomcp__togoid_getAllRelation"", ""input"": {}}, {""name"": ""mcp__togomcp__togoid_getRelation"", ""input"": {""source"": ""reactome_pathway"", ""target"": ""go""}}, {""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""R-HSA-109581,R-HSA-109606,R-HSA-109582"", ""route"": ""reactome_pathway,go"", ""limit"": 100}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""apoptosis cell cycle metabolism signaling immune"", ""types"": [""Pathway""], ""rows"": 50}}, {""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""R-HSA-1640170,R-HSA-109581,R-HSA-69620,R-HSA-1280215,R-HSA-162582,R-HSA-392499,R-HSA-168256,R-HSA-1266738,R-HSA-73857,R-HSA-74160"", ""route"": ""reactome_pathway,go"", ""limit"": 1000}}, {""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""0006915,0007049,0019538,0000075,0006366,0006351"", ""route"": ""go,reactome_pathway"", ""limit"": 1000}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006915""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0007049""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0000075""}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""metabolism"", ""types"": [""Pathway""], ""rows"": 30}}, {""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""R-HSA-1430728,R-HSA-15869,R-HSA-189445,R-HSA-380612,R-HSA-8964540,R-HSA-1660662,R-HSA-8982491,R-HSA-351202,R-HSA-71288,R-HSA-5652084"", ""route"": ""reactome_pathway,go"", ""limit"": 1000}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""signal transduction DNA repair translation transcription"", ""types"": [""Pathway""], ""rows"": 20}}, {""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""R-HSA-162582,R-HSA-186763,R-HSA-73894,R-HSA-72766,R-HSA-8953854"", ""route"": ""reactome_pathway,go"", ""limit"": 1000}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0008152""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006412""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006281""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006351""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0055086""}}]",CRITICAL,GO biological processes with Reactome: prefix in hasDbXref property,"COMPLEX QUERY requiring cross-reference knowledge.

Databases/Resources: GO

Knowledge Required:
- hasDbXref property for cross-references
- STRSTARTS filter for 'Reactome:' prefix
- Namespace filtering for biological_process
- FROM clause for consistent results

Without proper knowledge: Cannot identify Reactome cross-references.

Verified in go_exploration.md Pattern 7."
92,2026-02-01,Specificity,What are all the ancestor biological processes of 'mitophagy' in Gene Ontology?,True,False,True,0.6923076923076923,"I need to clarify that I should be careful about providing a complete hierarchical path without access to the current Gene Ontology database, as GO is regularly updated. However, I can provide you with the typical ancestor biological processes for mitophagy based on my training knowledge.

Mitophagy (GO:0000422 - autophagy of mitochondrion) typically has the following ancestor biological processes in the Gene Ontology hierarchy:

1. **mitophagy** (GO:0000422)
   - is_a: **autophagy** (GO:0006914)
     - is_a: **catabolic process** (GO:0009056)
       - is_a: **metabolic process** (GO:0008152)
         - is_a: **biological_process** (GO:0008150) [root]
   
   - is_a: **mitochondrion disassembly** (GO:0061726)
     - is_a: **organelle disassembly** (GO:0043462)
       - is_a: **cellular component disassembly** (GO:0022411)
         - is_a: **cellular process** (GO:0009987)
           - is_a: **biological_process** (GO:0008150) [root]

The main ancestral path goes through:
- Autophagy → Catabolic process → Metabolic process → Biological process
- Mitochondrion disassembly → Organelle disassembly → Cellular component disassembly → Cellular process → Biological process

**Note:** GO structure can be complex with multiple inheritance paths, and terms/relationships may have been updated since my training data. For the most current and complete information, I recommend checking the official Gene Ontology database directly.",,9.113476991653442,58,416,True,True,0.9230769230769231,"Perfect! I now have all the ancestor biological processes of mitophagy. Let me organize this information in a clear hierarchical structure for you.

## All Ancestor Biological Processes of Mitophagy (GO:0000423)

Here is the complete hierarchy of ancestor biological processes for **mitophagy**, from most specific to most general:

### Hierarchical Path 1 (through macroautophagy):
1. **Mitophagy** (GO:0000423) - The selective autophagy process in which a mitochondrion is degraded by macroautophagy
   ↑
2. **Macroautophagy** (GO:0016236) - The autophagic process that proceeds via the formation of an autophagosome
   ↑
3. **Autophagy** (GO:0006914) - The cellular catabolic process in which cells digest cellular materials
   ↑
4. **Catabolic process** (GO:0009056) - Biochemical pathways by which organisms break down substances
   ↑
5. **Metabolic process** (GO:0008152) - Biochemical pathways by which organisms transform chemical substances
   ↑
6. **Cellular process** (GO:0009987) - Any process carried out at the cellular level
   ↑
7. **Biological process** (GO:0008150) - Execution of a genetically-encoded biological module or program
   ↑
8. **Process** (BFO:0000015) - An occurrent that has temporal proper parts
   ↑
9. **Occurrent** (BFO:0000003) - An entity that has temporal parts and develops through time

### Hierarchical Path 2 (through autophagy of mitochondrion):
Mitophagy also has another direct parent:
- **Autophagy of mitochondrion** (GO:0000422) - The autophagic process in which mitochondria are delivered to a vacuole and degraded

### Additional parallel ancestor:
- **Process utilizing autophagic mechanism** (GO:0061919) - A cellular process involving delivery of cytoplasm to lysosomes via non-endocytic pathways

### Summary of Unique Biological Process Ancestors:
The biological process ancestors specific to the Gene Ontology (excluding the upper-level BFO ontology terms) are:

1. **Macroautophagy** (GO:0016236)
2. **Autophagy of mitochondrion** (GO:0000422)
3. **Autophagy** (GO:0006914)
4. **Process utilizing autophagic mechanism** (GO:0061919)
5. **Catabolic process** (GO:0009056)
6. **Metabolic process** (GO:0008152)
7. **Cellular process** (GO:0009987)
8. **Biological process** (GO:0008150)

These ancestors reflect that mitophagy is fundamentally a specialized type of autophagy that specifically targets mitochondria for degradation, and it falls under the broader categories of cellular catabolism and metabolism.",,25.31623101234436,12,1000,43579,65547,"mcp__ols__searchClasses, mcp__ols__getAncestors","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""mitophagy"", ""ontologyId"": ""go""}}, {""name"": ""mcp__ols__getAncestors"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0000423""}}]",CRITICAL,"Ancestor terms including autophagy (GO:0006914), catabolic process, cellular process, and process utilizing autophagic mechanism","COMPLEX QUERY requiring full hierarchy traversal.

Databases/Resources: GO

Knowledge Required:
- rdfs:subClassOf traversal for ancestor path
- FROM clause for consistent results
- STRSTARTS filter for GO URIs
- Transitive closure for complete ancestors

Without proper knowledge: Missing FROM clause or incorrect traversal pattern.

Verified in go_exploration.md Pattern 6."
93,2026-02-01,Currency,What experimental methods have been used to determine BRCA1 protein structures?,True,True,True,1.0,"Several experimental methods have been used to determine BRCA1 protein structures, though it's worth noting that obtaining complete structures of BRCA1 has been challenging due to its large size (~1,863 amino acids) and intrinsically disordered regions.

## Main Experimental Methods:

### 1. **X-ray Crystallography**
- **RING domain**: The N-terminal RING domain of BRCA1 in complex with BARD1 RING domain has been solved by X-ray crystallography, revealing their heterodimerization interface
- **BRCT domains**: The C-terminal tandem BRCT repeats have been extensively studied by crystallography, both alone and in complex with phosphopeptides

### 2. **Nuclear Magnetic Resonance (NMR) Spectroscopy**
- Used to study smaller, soluble domains of BRCA1
- Particularly useful for examining the RING domain and understanding its zinc-binding properties
- Has provided insights into domain dynamics and flexibility

### 3. **Cryo-Electron Microscopy (Cryo-EM)**
- More recently employed to study larger BRCA1 complexes
- Particularly useful for examining BRCA1 in the context of multi-protein assemblies (e.g., with partner proteins in DNA repair complexes)

### 4. **Small-Angle X-ray Scattering (SAXS)**
- Used to obtain low-resolution structural information about BRCA1 domains and their complexes in solution
- Helpful for understanding overall shape and conformational changes

## Key Challenges:
- Much of BRCA1 remains structurally uncharacterized due to intrinsically disordered regions
- Full-length BRCA1 structure has not been solved
- Most structural studies focus on individual functional domains rather than the intact protein",,10.129666805267334,53,422,True,True,0.9,"Based on my search of structural databases and scientific literature, I can provide you with a comprehensive overview of the experimental methods used to determine BRCA1 protein structures.

## Experimental Methods for BRCA1 Structure Determination

According to PubMed and the Protein Data Bank (PDB), three main experimental techniques have been used to determine BRCA1 protein structures:

### 1. **X-ray Crystallography**

This is the most extensively used method for BRCA1 structural studies, with numerous structures deposited in the PDB. X-ray crystallography has been particularly successful for determining structures of:

- **BRCT domains** (BRCA1 C-terminal repeats) - multiple crystal structures showing these domains in various states:
  - In complex with phosphorylated peptides from interaction partners (Abraxas, Bach1 helicase, CtIP, ATRIP, BAAT)
  - Disease-associated mutations and their structural consequences
  - Both tandem BRCT domains and individual domains

- **RING domain** - Crystal structures of the BRCA1/BARD1 RING-domain heterodimer complex

- **BRCA1-A complex** - The crystal structure of this larger assembly (PDB: 6gvw)

As noted in the review by Sun et al. (2019), ""structural information of the other major players involved, such as BRCA1... has been limited to crystal structures of isolated domains"" [(DOI: 10.1007/s00018-019-03365-1)](https://doi.org/10.1007/s00018-019-03365-1).

### 2. **Nuclear Magnetic Resonance (NMR) Spectroscopy**

NMR has been used to solve solution structures of BRCA1 domains, including:

- Solution structure of the BRCA1/BARD1 RING-domain heterodimer (PDB: 1jm7)
- Solution structure of the BRCT-c domain from human BRCA1 (PDB: 1oqa)
- Solution NMR structure of the coiled-coil BRCA1-PALB2 heterodimer (PDB: 7k3s)

NMR provides the advantage of studying protein structure and dynamics in solution, which can reveal conformational flexibility not captured in crystal structures.

### 3. **Cryogenic Electron Microscopy (Cryo-EM)**

This is the newest and increasingly important technique for BRCA1 structural studies, particularly for large complexes that are difficult to crystallize. Recent cryo-EM structures include:

- **BRCA1-BARD1 E3 ligase complexes bound to nucleosomes** (PDB: 7jzv, 7lyb, 7lyc, 8grq, 8off)
- **BRCA1-A complex** with improved resolution

According to Jiang et al. (2022), ""advances in single particle cryo electron microscopy"" have led to ""higher resolution structural models"" of key DNA repair proteins [(DOI: 10.1083/jcb.202111050)](https://doi.org/10.1083/jcb.202111050). Their study used ""cryogenic-electron microscopy (cryo-EM) analyses of isolated BRCA1-A complexes"" combined with chemical cross-linking and mass spectrometry.

Deng et al. (2021) highlighted that cryo-EM has enabled visualization of BARD1 (BRCA1's binding partner) bound to nucleosomes, revealing ""bivalent recognition of histone marks by BARD1"" [(DOI: 10.1016/j.tcb.2021.06.005)](https://doi.org/10.1016/j.tcb.2021.06.005).

### Summary

The PDB contains **273 BRCA1-related structures**, demonstrating the extensive use of these methods. The historical progression shows:
- **Early 2000s-2010s**: Predominantly X-ray crystallography of isolated domains
- **2000s-present**: NMR for solution structures of smaller domains and protein-protein interaction regions
- **2020s**: Revolutionary cryo-EM structures of full-length or near-full-length BRCA1 in complex with its partners and DNA substrates

The combination of these complementary techniques has provided increasingly detailed insights into BRCA1 structure, function, and disease-causing mutations, with cryo-EM now enabling visualization of BRCA1 in its native functional contexts within large macromolecular assemblies.",,68.22503900527954,331,2458,13728,199757,"mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""BRCA1"", ""limit"": 50}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX pdb: <https://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX pdbo: <https://rdf.wwpdb.org/pdb/>\n\nSELECT DISTINCT ?pdb_id ?title ?method\nWHERE {\n  ?entry rdf:type pdb:datablock ;\n         pdb:has_struct_keywordsCategory ?keywords ;\n         pdb:has_exptlCategory ?exptl .\n  \n  ?keywords pdb:has_struct_keywords ?kw .\n  ?kw pdb:struct_keywords.pdbx_keywords ?title .\n  FILTER(CONTAINS(LCASE(?title), \""brca1\""))\n  \n  ?exptl pdb:has_exptl ?exp .\n  ?exp pdb:exptl.method ?method .\n  \n  ?entry pdb:has_entryCategory ?entrycat .\n  ?entrycat pdb:has_entry ?e .\n  ?e pdb:entry.id ?pdb_id .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdb: <https://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX pdbo: <https://rdf.wwpdb.org/pdb/>\n\nSELECT DISTINCT ?pdb_id ?method\nWHERE {\n  VALUES ?pdb_id { \""4Y18\"" \""7JZV\"" \""1JM7\"" \""7LYB\"" \""1OQA\"" \""7K3S\"" \""1L0B\"" \""1T15\"" \""6GVW\"" \""8GRQ\"" }\n  \n  ?entry pdb:has_entryCategory ?entrycat .\n  ?entrycat pdb:has_entry ?e .\n  ?e pdb:entry.id ?pdb_id .\n  \n  ?entry pdb:has_exptlCategory ?exptl .\n  ?exptl pdb:has_exptl ?exp .\n  ?exp pdb:exptl.method ?method .\n}\n""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""BRCA1 protein structure determination X-ray crystallography NMR cryo-EM"", ""max_results"": 20}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""BRCA1 crystal structure"", ""max_results"": 20}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""BRCA1 NMR structure"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""BRCA1 cryo-EM structure"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""34215490"", ""35938958"", ""28692916"", ""31748913"", ""26548611"", ""38084173"", ""41393746""]}}]",VALUABLE,"X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy have been used for BRCA1 structures","COMPLEX QUERY requiring cross-reference and method knowledge.

Databases/Resources: PDB

Knowledge Required:
- UniProt cross-reference for P38398 filtering
- exptl.method property for experimental technique
- GROUP BY for method distribution
- struct_ref category for UniProt links

Without proper knowledge: Cannot combine UniProt filtering with method extraction.

Verified in pdb_exploration.md Pattern 2."
94,2026-02-01,Currency,What drugs have been developed for Type 2 diabetes with their development stages?,True,True,True,0.6153846153846154,"# Drugs Developed for Type 2 Diabetes

Type 2 diabetes has numerous drug treatments across various development stages. Here's an overview:

## **Approved/Marketed Drugs**

### Oral Medications:
- **Metformin** (Glucophage) - First-line treatment, biguanide class
- **Sulfonylureas**: Glipizide, Glyburide, Glimepiride
- **DPP-4 Inhibitors**: Sitagliptin (Januvia), Saxagliptin, Linagliptin, Alogliptin
- **SGLT2 Inhibitors**: Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana)
- **Thiazolidinediones**: Pioglitazone, Rosiglitazone
- **Meglitinides**: Repaglinide, Nateglinide
- **Alpha-glucosidase Inhibitors**: Acarbose, Miglitol

### Injectable Medications:
- **GLP-1 Receptor Agonists**: 
  - Exenatide (Byetta)
  - Liraglutide (Victoza)
  - Semaglutide (Ozempic, Wegovy)
  - Dulaglutide (Trulicity)
  - Tirzepatide (Mounjaro) - dual GLP-1/GIP agonist

- **Insulins**: Multiple formulations (rapid, long-acting, intermediate)

## **Drugs in Development Stages**

### Phase 3 Clinical Trials:
- Various next-generation GLP-1 receptor agonists
- Novel insulin formulations
- Combination therapies

### Phase 2 Clinical Trials:
- Glucagon receptor antagonists
- New SGLT inhibitor variants
- Metabolic pathway modulators

### Phase 1:
- Novel target mechanisms
- Gene therapies (early research)

The field continues to evolve with focus on combination therapies and drugs addressing multiple metabolic pathways.",,9.626978874206543,53,520,True,True,0.6153846153846154,"Based on the information retrieved from PubMed and biomedical databases, here's a comprehensive overview of drugs developed for Type 2 diabetes and their development stages:

## Drugs for Type 2 Diabetes by Drug Class and Development Stage

### **1. Approved and Widely Used Medications**

#### **Biguanides**
- **Metformin** (CHEMBL1431) - **FDA Approved**
  - First-line treatment for Type 2 diabetes
  - Reduces hepatic glucose production
  - Gold standard therapy for decades

#### **SGLT-2 Inhibitors (Sodium-Glucose Cotransporter-2 Inhibitors)**
- **Empagliflozin** (CHEMBL2107830) - **FDA Approved**
- **Dapagliflozin** - **FDA Approved**
- **Canagliflozin** - **FDA Approved**
  - Mechanism: Reduce glucose reabsorption in kidneys
  - Benefits: Cardiovascular and nephro-protective effects
  - According to PubMed research, these agents are associated with beneficial metabolic, cardio-, and nephro-protective effects independent of their antidiabetic properties ([DOI](https://doi.org/10.2174/0115733998419380251126073540))

#### **GLP-1 Receptor Agonists (Glucagon-like Peptide-1)**
- **Semaglutide** (CHEMBL2108724) - **FDA Approved**
- **Liraglutide** - **FDA Approved**
- **Dulaglutide** - **FDA Approved**
  - Mechanism: Enhance insulin secretion, reduce glucagon, slow gastric emptying
  - Benefits: Weight loss, cardiovascular benefits
  - According to recent PubMed studies, GLP-1RAs have become an essential drug class offering proven benefits in glycemic control, weight reduction, and cardiovascular and renal protection ([DOI](https://doi.org/10.1172/JCI194742))

#### **DPP-4 Inhibitors (Dipeptidyl Peptidase-4)**
- **Sitagliptin** (CHEMBL1422) - **FDA Approved**
  - Mechanism: Prevent breakdown of incretin hormones
  - Improve glycemic control without weight gain

#### **Thiazolidinediones (TZDs)**
- **Pioglitazone** - **FDA Approved**
  - Target: PPAR-gamma receptors (CHEMBL235)
  - Improve insulin sensitivity

#### **Sulfonylureas**
- **Glipizide** - **FDA Approved**
- **Glyburide** - **FDA Approved**
  - Mechanism: Stimulate insulin secretion

#### **Insulin Therapies**
- **Insulin Glargine** (CHEMBL1201497) - **FDA Approved**
- **Insulin Lispro** (CHEMBL1201538) - **FDA Approved**
- **Insulin Aspart** (CHEMBL1201496) - **FDA Approved**
  - Long-acting and rapid-acting formulations

### **2. Emerging Combination Therapies**

According to PubMed research, **combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists** represents a promising therapeutic approach. These combinations achieve synergistic interactions with different mechanisms of action and confer additional benefits beyond single-agent therapy ([DOI](https://doi.org/10.2174/0115733998419380251126073540)).

### **3. Precision Medicine Approaches - In Development**

Recent research from PubMed highlights that precision medicine approaches are being developed to personalize GLP-1RA treatment based on:
- Clinical factors
- Genetic factors
- Predictive models integrating routine clinical data

These approaches show considerable promise in identifying optimal Type 2 diabetes treatment based on individual patient characteristics ([DOI](https://doi.org/10.1172/JCI194742)).

### **Development Stage Summary:**

- **Phase 4 (Post-Marketing)**: Most of the drugs listed above are FDA-approved and in widespread clinical use
- **Phase 3/4**: Combination therapies and new formulations
- **Ongoing Research**: Precision medicine applications, novel indications (e.g., cardiovascular/renal protection beyond diabetes), and optimized dosing strategies

### **Key Drug Targets Identified:**
From ChEMBL database searches, major therapeutic targets for Type 2 diabetes include:
- Peroxisome proliferator-activated receptor gamma (PPAR-γ) - CHEMBL235
- Calcium/calmodulin-dependent protein kinases (CAMKK1/2) - CHEMBL5256, CHEMBL5284
- Various insulin signaling pathway components

The field continues to evolve with new combination strategies and personalized treatment approaches showing promising results in clinical trials.",,77.314768075943,46,2878,10319,238798,"mcp__pubdictionaries__search, mcp__ols__search, mcp__togomcp__search_chembl_target, mcp__pubmed__search_articles, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubdictionaries__search"", ""input"": {""labels"": ""Type 2 diabetes, diabetes mellitus type 2"", ""dictionary"": ""MONDO""}}, {""name"": ""mcp__ols__search"", ""input"": {""query"": ""Type 2 diabetes mellitus""}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""diabetes mellitus type 2"", ""limit"": 30}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""type 2 diabetes drug development clinical trials"", ""max_results"": 10}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""metformin"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""insulin glargine"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""sitagliptin"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""empagliflozin"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""semaglutide"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?molecule ?moleculeName ?maxPhase ?drugType\nWHERE {\n  ?molecule a chembl:SmallMolecule ;\n            chembl:hasMolecule/chembl:molecularWeight ?mw ;\n            chembl:pref_name ?moleculeName ;\n            chembl:hasIndication ?indication .\n  ?indication skos:prefLabel ?indicationLabel .\n  \n  OPTIONAL { ?molecule chembl:highestDevelopmentPhase ?maxPhase }\n  OPTIONAL { ?molecule chembl:drugType ?drugType }\n  \n  FILTER(REGEX(?indicationLabel, \""diabetes\"", \""i\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""type 2 diabetes mellitus drugs approved FDA 2020-2024"", ""max_results"": 15, ""date_from"": ""2020"", ""date_to"": ""2024""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molecule ?name ?phase\nWHERE {\n  ?molecule a chembl:SmallMolecule ;\n            chembl:pref_name ?name .\n  OPTIONAL { ?molecule chembl:highestDevelopmentPhase ?phase }\n  \n  FILTER(?name IN (\""METFORMIN\"", \""SITAGLIPTIN\"", \""EMPAGLIFLOZIN\"", \""SEMAGLUTIDE\"", \""LIRAGLUTIDE\"", \""DULAGLUTIDE\"", \""INSULIN GLARGINE\"", \""PIOGLITAZONE\"", \""GLIPIZIDE\"", \""GLYBURIDE\"", \""DAPAGLIFLOZIN\"", \""CANAGLIFLOZIN\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""type 2 diabetes therapeutics drug classes review"", ""max_results"": 5, ""date_from"": ""2022""}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41572751"", ""41552827"", ""41542765""]}}]",VALUABLE,"Type 2 diabetes drugs with development phases: METFORMIN (phase 4), GLIPIZIDE (phase 4), SITAGLIPTIN (phase 4), etc.","COMPLEX QUERY requiring indication and phase knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugIndication entity model
- hasMeshHeading for disease filtering
- highestDevelopmentPhase for status
- CONTAINS for indication keyword

Without proper knowledge: Cannot navigate DrugIndication model.

Verified in chembl_exploration.md Pattern 4."
95,2026-02-01,Precision,What is the chromosomal location of the BRCA1 gene?,True,True,True,1.0,"The BRCA1 gene is located on **chromosome 17**, specifically at position **17q21.31**.

This means it's on the long arm (q arm) of chromosome 17, in region 2, band 1, sub-band 31. BRCA1 is a tumor suppressor gene that plays a crucial role in DNA repair, and mutations in this gene are associated with increased risk of breast and ovarian cancers.",,3.3040530681610107,53,99,True,True,1.0,"The **BRCA1 gene** is located on **chromosome 17** at the cytogenetic band **17q21.31**.

More specifically, according to the current genome assembly (GRCh38/hg38):
- **Chromosome**: 17
- **Cytogenetic location**: 17q21.31
- **Genomic coordinates**: 43,044,294 to 43,170,326 base pairs
- **Size**: Spans approximately 126 kb (126,032 base pairs)
- **Exons**: Contains 31 exons

The ""17q21.31"" designation means:
- **17** = Chromosome 17
- **q** = Long arm of the chromosome (as opposed to ""p"" for short arm)
- **21.31** = Specific band and sub-band location

BRCA1 encodes a tumor suppressor protein involved in DNA repair and genomic stability. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers.",,27.323749780654907,21,696,5306,136328,"mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRCA1 AND human[organism]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""7157""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRCA1[Gene Name] AND Homo sapiens[Organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""672""]}}]",VALUABLE,17q21.31,"SIMPLE QUERY - Straightforward gene property lookup.

Method: ClinVar gene entity lookup for cytogenetic_location

Demonstrates when basic gene property lookups suffice.

Verified in clinvar_exploration.md Pattern 8."
96,2026-02-01,Precision,What is the equation for Rhea reaction RHEA:10000?,True,False,False,0.0,"I don't have access to specific RHEA reaction identifiers and their corresponding equations in my training data. RHEA is a comprehensive database of biochemical reactions, and RHEA:10000 would be a specific reaction entry in that database.

To find the equation for RHEA:10000, you would need to:
1. Visit the RHEA database directly at https://www.rhea-db.org/
2. Search for the identifier ""RHEA:10000""
3. View the complete reaction equation with all substrates, products, and cofactors

I cannot provide the specific equation for this reaction identifier with certainty from my training knowledge alone.",,4.457872152328491,53,149,True,False,0.4,"The equation for Rhea reaction RHEA:10000 is:

**H₂O + pentanamide = NH₄⁺ + pentanoate**

This represents a hydrolysis reaction where water reacts with pentanamide to produce ammonium ion and pentanoate.",,11.539390802383423,9,225,530,52264,mcp__togomcp__run_sparql,"[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?equation\nWHERE {\n  <http://rdf.rhea-db.org/10000> rh:equation ?equation .\n}\n""}}]",CRITICAL,Pentanamide + H2O = pentanoate + NH4+ (amidase reaction),"SIMPLE QUERY - Straightforward reaction lookup.

Method: Direct SPARQL lookup of rhea:equation for RHEA:10000

Demonstrates when basic property lookups suffice.

Verified in rhea_exploration.md simple queries section."
